Rhythm Pharmaceuticals, Inc. (RYTM) Discusses FDA Approval of IMCIVREE for Acquired Hypothalamic Obesity March 19, 2026 7:00 PM EDT
Company Participants
David Connolly – Head of Investor Relations & Corporate Communications
David Meeker – Chairman, President & CEO
Jennifer Chien – Executive VP & Head of North America
Alicia Fiscus – Senior VP & Head of Global Regulatory Affairs
Conference Call Participants
Simone Nasroodin – Wells Fargo Securities, LLC, Research Division
Tazeen Ahmad – BofA Securities, Research Division
Rohit Bhasin – Morgan Stanley, Research Division
Corinne Jenkins – Goldman Sachs Group, Inc., Research Division
Samantha Semenkow – Citigroup Inc., Research Division
Jonathan Wolleben – Citizens JMP Securities, LLC, Research Division
Brian Conley – Leerink Partners LLC, Research Division
Ellen Horste – TD Cowen, Research Division
Boran Wang – Guggenheim Securities, LLC, Research Division
Anthea Li – Jefferies LLC, Research Division
Lisa Walter – RBC Capital Markets, Research Division
Julian Pino – Stifel, Nicolaus & Company, Incorporated, Research Division
Presentation
Operator
Good day, and thank you for standing by. Welcome to the Rhythm Pharmaceuticals Conference Call. [Operator Instructions]
Please be advised that today’s conference is being recorded. I would now like to hand the conference over to your first speaker today, David Connolly, Investor Relations. Please go ahead.
David Connolly
Head of Investor Relations & Corporate Communications
Thank you, Marvin. This evening, we issued a press release announcing FDA approval of IMCIVREE for patients with acquired hypothalamic obesity. You can access the press release as well as the slides that we will be reviewing tonight by going to the Investors section on our website. Listed on Slide 3 are the speakers for tonight’s call. David Meeker, Chair, President and Chief Executive Officer of Rhythm; Jennifer Lee, Executive Vice President, Head of North America; and Hunter Smith, our Chief Financial Officer; and Alicia Fiscus, our Senior Vice President, Head of Global Regulatory Affairs, are also on the line to answer questions.
